Despite the headline circulating online, there is no verified $1.5 billion settlement between Eli Lilly, Novo Nordisk, and Sanofi over insulin price-fixing. That figure appears to stem from a conflation of data points — most likely Eli Lilly’s reported $1.5 billion in insulin sales and marketing spending between 2014 and 2018 — rather than any actual court-approved payout. What is real, and what consumers should be paying attention to, is a sprawling, multi-front legal battle over insulin pricing that has already produced tangible results for patients, even as the largest federal case remains unresolved.
The insulin pricing litigation landscape in 2026 involves 444 lawsuits consolidated in a federal multidistrict litigation (MDL 3080) in New Jersey, state attorney general settlements that have capped insulin costs at $35 per month in Minnesota, and a landmark FTC settlement with Express Scripts projected to save patients up to $7 billion over ten years. For anyone who has paid inflated prices for insulin over the past decade, the question is not whether the pharmaceutical industry engaged in price manipulation — multiple courts and regulators have found sufficient evidence to proceed — but how and when affected consumers will see compensation.
Table of Contents
- What Is the Insulin Price-Fixing Class Action Against Eli Lilly, Novo Nordisk, and Sanofi?
- Why the $13.5 Million Eli Lilly Settlement Fell Apart
- Minnesota’s $35 Insulin Cap — A State-Level Model That Actually Worked
- How the FTC’s Express Scripts Settlement Could Save You More Than Any Class Action
- Common Pitfalls for Consumers Tracking Insulin Litigation
- What the $22.4 Billion Revenue Figure Tells Us About Potential Damages
- What Comes Next in the Insulin Pricing Fight
- Frequently Asked Questions
What Is the Insulin Price-Fixing Class Action Against Eli Lilly, Novo Nordisk, and Sanofi?
The federal insulin pricing class action is centralized as MDL No. 3080 in the U.S. District Court for the District of New Jersey, under the supervision of Judge Brian R. Martinotti. As of January 2026, 444 individual lawsuits have been consolidated into this proceeding. The core allegation is that the three dominant insulin manufacturers — Eli Lilly, Novo Nordisk, and Sanofi, who collectively control the vast majority of the U.S.
Insulin market — worked in concert to raise consumer insulin prices by more than 150 percent over a five-year period. The plaintiffs argue this was not the result of independent business decisions but a coordinated scheme facilitated in part by opaque relationships with pharmacy benefit managers. To put the financial scale in perspective, Eli Lilly’s insulin product line alone generated $22.4 billion in revenue between 2014 and 2018, with the company spending $1.5 billion on insulin sales and marketing during that same window. Those figures matter because they illustrate the enormous financial incentives at play. For a Type 1 diabetic without adequate insurance, this translated to monthly costs that could exceed $1,000 for a drug that costs a fraction of that to produce. The case remains in pretrial and discovery stages with no global settlement announced, meaning consumers should be skeptical of any claim suggesting a finalized billion-dollar payout.
Why the $13.5 Million Eli Lilly Settlement Fell Apart
One of the more confusing developments in the insulin litigation was Eli Lilly’s agreement to a $13.5 million class-action settlement — a figure that itself struck many observers as remarkably low given the billions in insulin revenue at stake. The settlement was announced, preliminary paperwork was filed, and it appeared that at least one manufacturer was ready to resolve claims. However, the presiding judge declined to certify certain state-specific classes within the proposed settlement structure, effectively undermining the deal’s viability.
Following that judicial setback, both Eli Lilly and the plaintiffs pulled the plug on the $13.5 million agreement entirely. The plaintiffs subsequently filed a newer, revised version of their complaint against Lilly, signaling that they believe they can secure a substantially better outcome by continuing to litigate rather than accepting what amounted to pennies on the dollar. This is an important cautionary note for consumers monitoring the case: settlements can collapse, and a headline announcing a deal does not guarantee money in anyone’s pocket. If you filed a claim related to the Lilly settlement, that claim is no longer active, and you should watch for updates from the MDL court regarding next steps.
Minnesota’s $35 Insulin Cap — A State-Level Model That Actually Worked
While the federal litigation grinds forward, Minnesota Attorney General Keith Ellison secured separate settlements with all three insulin manufacturers that have already produced concrete results for residents of that state. Eli Lilly settled in February 2024, Novo Nordisk followed with its own agreement, and Sanofi finalized its deal in July 2024. Each settlement caps monthly out-of-pocket insulin costs at $35 for Minnesota consumers, including uninsured patients, and each cap lasts for five years. For a Minnesota resident who was previously paying $300 or more per month for insulin, this represents an immediate and dramatic reduction in cost — roughly $3,180 in annual savings at the low end.
The settlements were negotiated outside of the federal MDL and apply only to Minnesotans, which means residents of other states do not benefit directly. However, the Minnesota model has become a blueprint that other state attorneys general are studying. If you live outside Minnesota, it is worth checking whether your state AG has initiated similar proceedings. Several states have introduced or passed insulin price cap legislation independent of any settlement, though the enforcement mechanisms and coverage details vary significantly from state to state.
How the FTC’s Express Scripts Settlement Could Save You More Than Any Class Action
On February 4, 2026, the Federal Trade Commission secured what it called a landmark settlement with Express Scripts, one of the three largest pharmacy benefit managers in the United States. The FTC had sued Express Scripts, along with Optum Rx and CVS Caremark, in September 2024, alleging that these PBMs inflated insulin costs through rebate practices that incentivized manufacturers to keep list prices high. The Express Scripts settlement requires the company to stop preferring high-list-price drugs when cheaper equivalents exist, to delink its compensation from drug price negotiations, and to base patient out-of-pocket costs on the net cost of the drug rather than the inflated list price. The projected impact is enormous: up to $7 billion in reduced patient costs over ten years, dwarfing any class-action settlement figure currently on the table.
Optum Rx and CVS Caremark are reportedly in “significant progress” settlement talks with the FTC, and similar terms for those companies would extend the savings further. The tradeoff here is structural versus compensatory. The FTC settlement does not put cash directly into the hands of consumers who overpaid in the past — it changes the pricing system going forward. If you are looking for reimbursement of past overpayments, you will need to wait for the federal class action or pursue individual claims. But if your primary concern is what you will pay for insulin next month, the PBM settlements may matter more to your daily life than the manufacturer lawsuits.
Common Pitfalls for Consumers Tracking Insulin Litigation
The single biggest risk for consumers following this litigation is acting on misinformation. The “$1.5 billion settlement” claim in the title of this article is itself an example — no such settlement exists, and anyone who tells you to file a claim for a share of $1.5 billion in insulin settlement funds is either confused or running a scam. Be especially wary of unsolicited emails, social media ads, or third-party websites promising large payouts from insulin lawsuits. Legitimate class action notices come from the court or court-appointed claims administrators, not from marketing firms.
Another limitation worth understanding is the difference between a settlement and a judgment. Even when a settlement is announced, it must go through preliminary approval, a fairness hearing, and final approval before any money is distributed. As the failed $13.5 million Lilly settlement demonstrated, deals can collapse at multiple points in this process. Consumers should also be aware that class action payouts are divided among all eligible claimants, which often means individual payments are far smaller than the headline number suggests. In a case involving millions of insulin users, even a billion-dollar settlement could translate to relatively modest per-person payments depending on the distribution formula.
What the $22.4 Billion Revenue Figure Tells Us About Potential Damages
The disclosure that Eli Lilly’s insulin line generated $22.4 billion in revenue between 2014 and 2018 — with $1.5 billion spent on sales and marketing — provides a window into the scale of potential damages if the federal case ever reaches a verdict or a meaningful settlement. Plaintiffs’ attorneys typically seek damages proportional to the alleged overcharge, which in this case involved price increases exceeding 150 percent.
If a court determined that even a fraction of those revenues were attributable to anticompetitive pricing, the resulting judgment could dwarf any settlement figure discussed so far. For context, treble damages under antitrust law could theoretically multiply any proven overcharge by three, though such outcomes are rare in settled cases.
What Comes Next in the Insulin Pricing Fight
The most consequential developments in 2026 and beyond will likely come from three directions. First, the MDL 3080 proceedings in New Jersey will eventually move past discovery toward either a global settlement or trial — a process that could still take years but will define the largest pool of potential consumer compensation. Second, the FTC’s ongoing negotiations with Optum Rx and CVS Caremark, if they produce settlements comparable to the Express Scripts deal, would restructure insulin pricing across the majority of the U.S.
Pharmacy benefit system. Third, additional state attorneys general may follow Minnesota’s lead with manufacturer-specific settlements that deliver immediate cost relief to residents. For consumers, the practical advice is unglamorous but important: keep your pharmacy records, maintain documentation of what you paid out of pocket for insulin, and register for updates through the official New Jersey District Court insulin pricing litigation page. When a legitimate settlement is finalized, having organized records will make the claims process significantly faster and reduce the risk of your claim being denied for lack of documentation.
Frequently Asked Questions
Is there really a $1.5 billion insulin settlement I can file a claim for?
No. As of March 2026, no $1.5 billion settlement has been announced or approved in any insulin pricing case. The federal MDL 3080 remains in pretrial stages, and the only manufacturer settlement that was announced (Eli Lilly’s $13.5 million deal) was subsequently withdrawn. Be cautious of any website or service claiming otherwise.
How do I know if I qualify for insulin pricing class action compensation?
Eligibility criteria will be defined when and if a settlement is finalized in MDL 3080. Generally, consumers who purchased insulin manufactured by Eli Lilly, Novo Nordisk, or Sanofi and paid out-of-pocket costs inflated by the alleged pricing scheme would be potential class members. Keep your pharmacy receipts and insurance statements as documentation.
Does the $35 insulin cap apply to me?
The $35 monthly cap secured by Minnesota AG Keith Ellison applies only to Minnesota residents. However, separate from the litigation, the federal Inflation Reduction Act capped insulin copays at $35 per month for Medicare beneficiaries beginning in 2023. Some manufacturers have also voluntarily introduced $35 cap programs. Check with your insurer and pharmacy to understand your current options.
What is the FTC Express Scripts settlement and how does it help me?
The FTC secured a settlement with Express Scripts on February 4, 2026, requiring the pharmacy benefit manager to stop practices that inflated insulin costs. If your prescription benefits are managed by Express Scripts, you should see lower out-of-pocket costs going forward as the company implements net-cost-based pricing. The projected savings across all patients are up to $7 billion over ten years.
How long will the federal insulin class action take to resolve?
MDL cases of this complexity typically take several years from consolidation to resolution. With 444 lawsuits pending and the case still in discovery, a global settlement or trial verdict is unlikely before 2027 at the earliest. Consumers should prepare for a long process and avoid making financial decisions based on anticipated settlement payments.
Should I join a lawsuit or wait for the class action?
Most consumers are automatically included in the class action unless they opt out. You do not need to hire a lawyer or take any action to be part of the class. However, if you suffered unusually large financial losses due to insulin pricing — such as medical debt, bankruptcy, or rationing that led to hospitalization — consulting with an attorney about an individual claim may be worthwhile, as individual damages could exceed your share of a class settlement.